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ABSTRACT
cGMP-dependent protein kinase (PKG, cGPK) is a serine-threonine kinase of the AGCkinase family. Although PKG type Ia plays a prominent role in the control of blood-flow and
blood pressure, no current hypertension therapies target this enzyme.1 A PKG-targeted therapy
would establish a first-in-class treatment for patients with uncontrolled blood pressure and may
provide a clinically relevant alternative to existing antihypertensive therapies.
Dostmann et al. developed novel peptides derived from the crystal structure of PKG Ia,
which are helical in solution and found to activate the kinase independent of cGMP and were
demonstrated to lower blood pressure in vivo.2,3 Two consecutive phenylalanine residues were
identified as a central element of the putative pharmacophore within the full-length peptide.
However, a shortened peptide derivative, called S1.5 (here SP), was found to have increased potency and thus has been suggested as a potential lead compound for further development. The
aim of this thesis is to reevaluate the pharmacophore and specifically the role of the phenylalanine residues in context of the SP peptide.
In this study, analogs of SP were designed using an alanine-scanning approach to analyze
the role of specific amino acids in the activation mechanism. By employing recombinant PKG
Ia, kinetic parameters were determined using a specific radiometric assay.4,5
We found that substituting either or both phenylalanine residues for alanine did not impair the peptide’s potency or efficacy. However, deleting one phenylalanine greatly diminished
activity. This phenotype could be rescued by substituting either of two positively charged lysine
residues N-terminal to the pharmacophore for alanine. These results indicate that the interactions
between the kinase and these novel synthetic peptides are more complex and involve unidentified amino acids. Furthermore, the results presented here will serve to evaluate the role of N-terminal residues in peptide binding and the rescue phenotype discovered in this study.
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INTRODUCTION

Overview of PKG and cGMP
Cyclic-GMP dependent protein kinase (PKG, cGPK) is a signaling protein which is
widely distributed in eukaryotes. PKG isozymes are part of a larger family of basophilic AGC
protein kinases which also includes PKA and PKC.6 These kinases catalyze the transfer of the gphosphate from ATP to serine or threonine residues on basic substrate peptides and proteins.7
PKG is activated allosterically by 3’,5’-cyclic guanosine monophosphate (cGMP), unlike some
other protein kinases which are activated covalently through modifications such as phosphorylation.8
Three variants of PKG are known to exist in mammalian tissue: PKG Ia, PKG Ib, and
PKG II. PKG I isozymes are derived from the gene prkg 1 while PKG II is derived from a separate gene, prkg 2.7 PKG I isozymes are found in smooth muscle, platelets, and specific neuronal
areas. Specifically, PKG Ia is most common in lung tissue, heart tissue, and dorsal root ganglia
while PKG Ib is found in platelets and hippocampal neurons. PKG II is found in small intestine
epithelium, the adrenal cortex, juxtaglomerular cells, chondrocytes, and neurons.7 All PKG
isoforms are essential signaling molecules in mammalian tissue, and they serve as the principle
receptors for cGMP.9 Additionally, all isoforms have the same general, highly homologous domain organization. The parallel homo-dimers are composed of N-terminal regulatory domains
encompassing two nucleotide binding sites, followed by C-terminal catalytic domains.10
As a classic second messenger molecule, cGMP plays a prominent role across a myriad
of species. In smooth muscle, production of cGMP can occur by nitric-oxide mediated activation
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of soluble guanylyl cyclase (sGC) or by natriuretic peptide activation of the membrane associated particulate guanylyl cyclase (pGC). In vascular smooth muscle, sGC is responsible for synthesis of cGMP,11 however both sGC and pGC covert guanosine triphosphate (GTP) to GMP in
other mammalian tissues. Activated cGMP has downstream targets in other tissues that contribute to processes such as regulating smooth muscle tone, platelet aggregation, bone growth and
development, renin release in the kidney, intestinal fluid secretion, and serotonin transport in the
brain.11 Phosphodiesterases (PDEs) hydrolyze cGMP to 5’-GMP. PDE-5 can be phosphorylated
by PKG itself which activates the enzyme and decreases intracellular levels of cGMP.12

PKG Ia and Smooth Muscle Regulation
PKG Ia plays a role in controlling constriction and relaxation of smooth muscle cells in
the central and peripheral vasculature.13 Smooth muscle contraction is a calcium-dependent process. Ca2+ binds calmodulin, which activates the myosin light chain kinase (MLCK). This kinase
phosphorylates myosin light chains, which leads to cross-bridge formation between myosin and
actin and therefore causes muscle contraction.14
PKG relaxes smooth muscle by decreasing calcium levels. First, PKG is activated
through a series of biological events referred to as the nitric-oxide (NO) signaling cascade. NO,
generated in the endothelium, diffuses into cells and binds to the heme group of soluble guanylyl
cyclase (sGC), which converts GTP to cGMP. This cGMP activates PKG Ia. PKG decreases intracellular calcium levels by several mechanisms. The primary mechanism is such that PKG
phosphorylates the large conductance Ca2+-activated K+ channel (KCa1.1, BKCa), which hyperpolarizes the membrane by increasing efflux of potassium. Hyperpolarization of the membrane inhibits voltage-dependent calcium channels, decreasing intracellular levels of Ca2+ responsible for
2

muscle contraction.3,15 Other substrates for PKG include phopsholamban (PLN), the inositol triphosphate receptor-associate cGMP-kinase substrate (IRAG), the regulator of G-protein signaling 2 (RGS2), and the Ras homolog gene family member A (RhoA)2 (Figure 1).

Figure 1. PKG signaling in vascular smooth muscle cells. Image from Osborne, 2011.2
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PKG Ia Structure
PKG Ia shows significant sequence homology to the other PKG isoforms. PKG Ia, like
the other isoforms, is a homodimer in which each monomer has an N-terminal regulatory domain
and a C-terminal catalytic domain (Figure 2). At the N-terminus of the kinase there is a dimerization domain (DD) where the two protomers interact.16,17 Facilitation of the homodimer at the
DD contributes to cooperative binding of cyclic nucleotides.18 A linker region connects the DD
to an auto-inhibitory (AI) domain and another linker region.19 Following this, there are two cyclic-GMP binding sites. The N-terminal binding site, or A site, demonstrates higher binding affinity than the C-terminal B site. This contrasts cyclic-nucleotide binding sites of other protein
kinases such as PKA, where the order of the high and low affinity sites is reversed.9,20 In addition, examination of cyclic nucleotide binding revealed that the A site was able to bind both
cGMP and cAMP.9 The difference between these sites may be due to the A-site being more solvent-exposed as well as the presence of an arginine residue in the B site. This could serve to
prime the kinase to be more sensitive to changes in cGMP levels under conditions of elevated
cAMP while still activate normally by cGMP when cAMP levels are low.9 At the C-terminus of
the B-site there is a region referred to as the switch helix domain (SW) which plays a role in interacting with the opposing protomer.20 This transitional domain bridges between the regulatory
and catalytic domains and is only found in type I isoforms. At the C-terminus of the SW helix
lies a motif called the “knob,” comprised of the amino acids FFANL. The “knob” interacts with a
hydrophobic “nest” located within the B binding site on the opposing protomer (Figures 3, 4).9
The successive phenylalanine residues provide the hydrophobicity for this interaction and the asparagine residue provides hydrogen bonding. Recent analysis of PKG Ia structure revealed this
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novel domains is critical to kinase’s function as disruption of the knob/nest interaction diminished both cooperativity and activation of the kinase.9 In the context of the full, dimeric enzyme,
creating a quadruple mutant with FF and NL residues in the knob changed to alanine caused a
marked shift in activation and cooperativity of the enzyme, demonstrating the importance of the
knob-nest interface.20 Finally, the SW is followed by the catalytic domain which contains binding regions for ATP and substrate.
Current models suggest that under inactive conditions, the catalytic domain interacts with
the regulatory domain and the switch helix. When bound to cGMP, the catalytic domains are released and the knobs on the switch helices interact with the two nests. It is believed that the dimer stays intact upon activation but undergoes significant conformational change. This lack of
dissociation marks the most distinct difference between it and protein kinase A (PKA).20

Figure 2. Organization of domains within PKG Ia: Dimerization Domain (DD), Auto-inhibitory Domain (AI), cyclic-nucleotide binding sites A and B, Switch Helix (SW) ATP-binding site (ATP), and substrate binding site.

5

Figure 3. Dimeric view of PKG78-355 crystal structure with cyclic-nucleotide binding sites and switch helices labeled. Image from Osborne, 2011.

Figure 4. Top view of switch helices with their neighboring protomer. Hydrophobic knobs are located at the end of the SW (blue) and bind
within the hydrophobic nest (orange) within the B-domain. Image from Osborne, 2011.
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Synthetic Peptide Activators
Recent developments in PKG-targeted therapy have looked to modulate PKG activity independent of cGMP. Upon solving the crystal structure for the fragment PKG78-355, it was determined that the two protomers interact via hydrophobic interactions between the switch helix segment and the B site on the opposing protomer. The isolated switch helix segment (residues 329358) proved to be helical in solution and was assessed to determine if this segment alone could
activate the kinase. Moon et al (2015) introduced a set of synthetic peptide activators (S-tides)
derived from the structure of the SW helix (Table 1). The full length peptide, named S1.1, was
able to activate PKG Ia with 80% efficacy compared to cGMP.3 To confirm that the primary
structure of this peptide is crucial to its function, a scramble peptide (S1.7) served as a negative
control.
Derivative S-tides were created that sequentially removed C-terminal amino acid residues
until the peptides no longer activated the kinase. This activity dropped off when knob residues
(FFANL) were deleted from the synthetic peptides (S1.3). This truncation also partially diminished helicity of the peptide. This truncation removes the proposed hydrophobic interactions provided by the phenylalanine residues as well as hydrogen bonding provided by the asparagine residue. To further probe the hydrophobic interaction provided by the phenylalanine residues, the
wild type sequence was next mutated in the knob region. Both phenylalanine residues in the
knob region were replaced with alanine, following the logic of alanine-scanning mutagenesis. In
brief, mutating residues to alanine removes side chain interactions due to the small, nonpolar
character of alanine. This peptide, termed S1.6, was unable to activate the kinase at all, supporting the hypothesis that the two phenylalanine residues are crucial for the peptide’s ability to activate the kinase.
7

Next, sequential truncations were made on the N-terminus of the peptide. These truncations increased the potency of each peptide to activate the kinase up until removal of the tyrosine
residue at position #7 in the parent peptide. Truncations beyond this point gradually lowered activity to zero. The peptide that showed the best activation, called S1.5, activated PKG Ia at concentrations as low as 3 µM, but failed to activate PKG Ib. In physiological context, these peptides were shown to increase open probability of large-conductance calcium-activated potassium
channels. In the same study, it was also demonstrated that S1.5 reduced myogenic tone in endothelium-denuded cerebral arteries via this mechanism.3
Though the role of the phenylalanine knob residues was assessed in context of the fulllength peptide (S1.1), it was never re-evaluated in the context of S1.5. This provided the basis for
the aims of this study. In this study, the S1.5 peptide is referred as “switch peptide” or SP.

Name

Sequence

Ka (µM)

Hill

S1.1

Ac-DVSNKAYEDAEAKAKYEAEAAFFANLKLSD-NH2

35 ± 4

2.2 ± 0.4

S1.7

Ac-ALKSENYADKVEFKDAKYEASALANEFADA-NH2

-

-

S1.6

Ac-DVSNKAYEDAEAKAKYEAEAAAAANLKLSD-NH2

-

-

S1.3

Ac-DVSNKAYEDAEAKAKYEAEAA-NH2

-

-

3 ±1

2.4 ± 0.6

S1.5 (SP)

Ac -YEDAEAKAKYEAEAAFFANLKLSD-NH2

Table 1. Novel S-tide names and sequences are listed with corresponding activation constants (Ka) and Hill coefficient (nH).3 Ka
indicates the concentration of activator which produces half maximal activation of the enzyme. A Hill coefficient above one indicates positive cooperativity in binding such that binding of one ligand facilitates binding of another.
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Relevance
Hypertension is a highly prevalent condition both in the United States and across the
globe and it has very serious outcomes. Despite there being a myriad of mediations to treat hypertension through various mechanisms, there remains significant unmet need for those individuals who do not respond to available treatments. The nitric oxide pathway has been a major target
for these drugs for decades, however there is no current treatment which targets PKG. Though
PKG may theoretically be a good target for this pathway, it is highly expressed throughout the
body and therefore may cause off-target effects. However, novel S-tides are isozyme specific and
therefore would target PKG Ia localized to the vascular smooth muscle and minimize off-target
effects. Additionally, these S-tides have been demonstrated to lower blood pressure in vivo in animal models of hypertension with L-NAME treated rats (B. Osborne and W. Dostmann unpublished data). Therefore, this research provides a pharmaceutical platform for first-in-class
agents to treat hypertension.

Experimental Methods for Measuring Kinase Activity
The kinetics of kinase enzymes can be determined by various methods. Enzyme-coupled
spectrophotometric assays couple the kinase-mediated phosphorylation of a substrate to colorimetric measurable reactions such as the conversion of phosphoenolpyruvate (PEP) to pyruvate
and lactate dehydrogenase (LDH)-mediated conversion of pyruvate and nicotinamide adenine
dinucleotide (NADH) to lactate and NAD+. The reaction is set up such that the kinase-mediated
reaction is the rate limiting step.21 By measuring NADH oxidation with a spectrophotometer the
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decrease in absorbance is used to determine the reaction rate. This assay type is particularly useful in that it takes measurements continuously, though other methods may be more efficient for
rapidly analyzing large sample numbers.22
Fluorescence can also be a useful tool in determining kinase kinetics. Fluorescence polarization (FP) and anisotropy (FA) are two widely used techniques used for binding assays of numerous biological signaling molecules. These assays rely on the principle that the polarization of
a fluorophore is inversely related to its rotation.23 The FP measurement is equal to the difference
between the intensity of emission light parallel and perpendicular to the excitation light, and
changes in this measurement are used to determine enzymatic velocity. Because Brownian motion decreases as molecular weight increases, the polarization of the fluorescent label is low
when attached to a small molecule and high when attached to a larger molecule.24 For assays examining serine-threonine kinases such as PKG, fluorescently-labeled high-affinity antibodies are
used which can discriminate between phosphorylated and non-phosphorylated residues such as
tyrosine.25
The transfer of radio-labeled phosphate groups from ATP to a kinase’s substrate, as it
was utilized in this study, can be measured to determine the enzyme’s kinetics. In this method,
32

P in the g position of ATP is transferred to a peptide or protein substrate by the kinase. This

32

P-labeled substrate can then be caught on a filter and quantified by scintillation counting.4,5 The

ionizing radiation given off by the decay of 32P interacts with aromatic hydrocarbons in the scintillation materials, either liquid or crystal, and results in an energy transfer. Electrons in the scintillation materials are transiently excited and emit photons upon returning to the ground state.26
These photons are caught by a detector, hereafter referred to as a “counter.” Radioactive assays
with scintillation counting were used in this experiment and are detailed in the methods section.
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AIMS AND HYPOTHESIS
Aim: To evaluate the pharmacophore of the switch peptide and to probe specific interactions between SP derivatives and PKG Ia.
Substitution of the two phenylalanine residues within the knob region of the full-length
synthetic helix (S1.1) were substituted for alanine, the resulting peptide (S1.6) exhibited no activity. This suggested that the phenylalanine residues interact with the nest and in way that is
necessary for kinase activation. N-terminal truncations of the full-length peptide led to a shortened peptide which displayed improved potency and now serves as the lead peptide for a new
pharmacological platform. However, the pharmacophore of the switch peptide (S1.5) has not
been revisited and solidified.

Hypothesis: The phenylalanine residues within the knob of the switch peptide provide a
crucial hydrophobic interaction with the nest which allow this peptide to activate the kinase.
Derivative peptides without these phenylalanine residues will be unable to efficiently interact with the kinase. Therefore, they will have a significantly reduced activation constant and
maximum velocity compared to the parent peptide, SP. This will be explored by using an alanine
scanning approach to create derivative peptides which have altered knob sequences. Peptide kinetics will be determined using a radioactive protein kinase assay.
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MATERIALS AND METHODS

Peptide Synthesis and Quality Control
The synthetic peptides were synthesized by Dr. Werner Tegge at the Helmholtz Centre
for Infection Research (Braunschweig, Germany). Peptides were synthesized via solid-phase
synthesis on Rapp S RAM Resin with a Syro multiple peptides synthesizer. Fmoc chemistry was
used with activation by TBTU / diisopropylethyl amine activation in tenfold excess. The reaction
time was 1 hour. The side chain protections were as followed: Asp, Glu, Syr, Tyr, and Thr with
t-Bu; Asn, Gln, and His with trityl group; Arg with Pmc; Lys and Trp with Boc. Peptides were
then cleaved from the resin and deprotected with TFA. Crude peptides were purified by highperformance liquid chromatography (HPLC) and characterized by MALDI-MS. Final products
were lyophilized from water.

Peptide Solutions
Peptides were put into solution and serially diluted to be used in the kinase assay. Top
stocks were made by calculating the milligram mass and volume of ddH2O required to create 1
mL of 2 mM solution for each peptide. Physical differences between peptides caused variability
in the amount of peptide that was able to be dissolved into solution. Once a top stock was made,
a serial dilution was performed such that concentrations were halved with each successive dilution. Final stock concentrations ranged from 2.5 µM to 1.25 mM. These concentrations were
confirmed using Nanodrop technology at l=276 nm with a molar coextinction coefficient of
2,840.
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Protein Expression, Purification, and Storage.
PKG Ia used in this study was expressed by Joseph Charles (Dostmann laboratory) using the
insect cell (Sf9) Bac-to-Bac baculovirus expression system.18 Nickel affinity chromatography
was used for purification and purified kinase was assayed with cGMP to ensure the resulting activity was consistent with previously determined data. The purified protein was stored in a buffer
containing 50 mM MES, 150 mM NaCl, 1 mM TCEP and 10% glycerol and stored in 20 µL aliquots at -80 °C.

P81 Phosphotransfer-Assay
Overview:
In order to measure the enzyme kinetics of PKG with various activators, a radioactive assay was used. This assay measures PKG-mediated phosphorylation of the substrate with the gphosphate of a 32P tagged ATP.4,27 The peptide substrate, called W15, has the sequence
TQAKRKKSLAMA, and its many positively charged residues allows it to bind to a phosphocellulose filter.28 The filter paper is then placed in a liquid scintillation counter where CPM can be
measured. These counts are analyzed to determine reaction velocity and the concentration at
which half-maximal activation is achieved (Ka).
Protocol:
To prep for the cGMP assay, reaction tubes were set up with increasing concentrations of
cGMP. Each reaction tube received 10 µL of the respective 10x cGMP stock. For each reaction,
a cocktail of reagents, hereafter referred to as “reaction mix,” was created. This reaction mix
consisted of 20 µL of 5x MES (250 mM MES pH 6.9, 5 mM MgOAc, 50 mM NaCl), 10 µL of
13

100 mM DTT, 10 µL of 10 mg/mL BSA, 10 µL of 100 µM W15, 10 µL of ddH2O, and 10 µL of
32

P-ATP.
Before the reaction mix was added to each tube, ATP was spiked with the radio-labeled

isotope. 32P -ATP was added to 1 mM ATP such the volume of P32-ATP was 1/100th the total
volume at the calibration date, and 1/50th the total volume after one half-life (14 days). To find
the specific activity of the spiked ATP, 15 µL of the mixture was blotted onto the P81 filters and
counted by liquid scintillation. Once the specific activity of the spiked ATP was determined, 70
µL of the reaction mix was added to each tube.
Each reaction was initiated with the addition of the kinase. PKG Ia was suspended in Enzyme Dilution Buffer (EDB) in 1:1000 dilution resulting in 8 ng of PKG per reaction. This dilution was used to initiate the phosphotransferase reaction. The reaction was allowed to run for 3
minutes and was terminated by blotting 25 µL of the reaction contents onto individually labeled
Whatman P81 filter papers. The filters were then washed four times in 1% phosphoric acid for
three minutes per wash. The purpose of the wash is to prevent non-specific binding and remove
excess 32P -ATP. The filters were then dried and placed into vials containing fluid comprised of
toluene, 45 mM 2,5-diphenyloxazole (PPO), and 0.36 mM 1,4-bis(5-phenyl-2- oxazolyl)benzene
(POPOP) so that CPM could be measured in a liquid scintillation counter.
Radiation given off by the 32P, now attached to the substrate which was caught on the
P81 filters, transiently elevates electrons in the aromatic hydrocarbons of the scintillation fluid.
As they return to the ground state, a photon is emitted which is detected by the counter. The output for each filter is reported in counts per minute measurement which was used to calculate the
enzyme velocity at each activator concentration.
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Variation for Peptide activators:
The study by Moon et al. (2015) illustrated that the binding of the peptide activators to
PKG is markedly slower than that of the natural activator, cGMP.3 Because of this, the experimental designed was modified such that the activators were allowed to incubate with the kinase
prior to the reaction being started. The protocol is as follows: 1.5 mL Eppendorf tubes were labeled and aliquoted with 10 µL of the experimental peptide at varying concentrations. The blank
and zero received 10 µL of ddH2O in place of the experimental peptide. PKG Ia was diluted in
the same manner as previously described and 20 µL of this PKG/EDB solution was added to the
reaction tubes—excepting the blank—and allowed to incubate at 30 °C with the peptide for 30
minutes. The necessity of this incubation time was previously established by the Dostmann lab
and it was demonstrated that the incubation had no negative effect on the enzyme itself. This reaction was initiated with 70 µL of the reaction mixed described above, consisting of 5x MES,
DTT, BSA, W15, 32P-ATP and ddH2O. The reaction was allowed to run for 3 minutes and terminated in the same manner as above. The P81 filters were washed and submerged in scintillation
fluid for counting as described (Figure 5).
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Figure 5. Work flow diagram for the phosphotransferase assay activating PKG with synthetic peptide activators.

Data Analysis
In order to evaluate the kinetics of each activator, raw experimental data was analyzed in
Microsoft Excel and Graphpad Prism 8TM. The liquid scintillation counter gives an output of
counts per minute (CPM) for each filter. After importing this data into Excel, the velocity for
each concentration is calculated by multiplying CPM by the blotting correction (0.25) and purity
correction (0.98) and divided by reaction time (3 minutes), concentration of protein (8 ng), and
specific activity (variable). This gives each velocity measurement with the units of µmol (PW15) / min*mg (PKG).
16

The resulting velocity measurements were then plotted against their corresponding activator concentration in Graphpad Prism 8TM. A nonlinear regression curve fit was performed with
log concentration versus velocity to determine the activation constant (Ka), Hill coefficient (nH),
Vmax, and Vmin. For each parameter, 95% confidence intervals calculated by GraphPad Prism 8TM
are provided.
To correct for variability in the Vmax of the cGMP control for each assay, results from
each peptide-activated assay were normalized such that the Vmax of the cGMP control represented 100%. This is referred to hereafter as “normalized velocity.”

3D Modeling
In order to further probe the interactions between the switch peptide and the kinase, 3D
modeling was implemented. The PyMol visualization program was used and PKG crystal structures were obtained from the protein data bank (PDB). The PDB entry used in this study, 3SHR,
was crystalized by Osborne et al (2011) and provides an interactive representation of PKG Ia as
shown in Figure 3.
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RESULTS
Controls: cGMP and SP
Control trials were run for both cGMP and the switch peptide SP. All results for the control were found to be within a similar range relative to previously published data. Assays performed using cyclic nucleotides, required a protocol as outlined in the methods, whereby the reactions were initiated by adding kinase to the individual reaction mixes. cGMP had an activation
constant (Ka) of 180 nM and it reached a maximum velocity of 6.5 µmol per min*mg while Vmin
was comparatively low with 0.3 µmol per min*mg as is typical for enzyme preparations performed in the presence of strong reducing agents such as TCEP, see Methods (Figure 6).13,18
Concentrations that resulted in maximal kinase activation level (8 µM cGMP) were used as a
control for each subsequent assay involving peptides. This allowed us to normalize each pep-

Velocity (µmol x min-1 x mg-1)

tide’s maximum velocity to the velocity of cGMP.
8
6
4
2
0
-10

-9

-8

-7

-6

-5

Activator

Vmin

Vmax

Hill (nH)

cGMP

0.31 ± 0.12

6.51± 0.12

1.68 ± 0.2

Ka (nM)
179 ± 14

n
4

-4

log[cGMP] (M)
Figure 6. Activation of PKG Ia with cGMP. The enzyme (1 nM, 8 ng per assay) was activated with increasing concentrations (4 nM – 16 µM)
of cGMP under non-preincubation conditions as described in the methods. The adjacent table summarizes the kinetics constants derived from
the reaction. Reaction velocities are given in µmols of substrate per minute and mg of PKG.
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The parent peptide, SP, was also used as a control. However, the assay had been changed
to accommodate the need for preincubation of the peptide with kinase, due to the peptide’s relatively slow activation of the kinase relative to cGMP, demonstrated by Moon et al (2015). Following a 30-minute preincubation period of kinase and various concentrations of peptide, reactions were initiated by addition of reaction mix. The activation constant for SP in this study was
found to be 7.2 µM and its maximal activation was 74% of cGMP (Figure 7). Derivative peptide
results are compared to these values. This Ka value is approximately 2-fold higher than previously reported. However, it was highly reproducible and is likely a reflection of the differences

B

6
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4

100

Normalized Velocity

A

Velocity (µmol x min-1 x mg-1)

in enzyme preparation protocols.29

2
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log[conc] (M)

Name

Sequence

SP

YEDAEAKAKYEAEAAFFANLKLSD

-6

-5

-4

log[SP] (M)

N. Vmin
9.20 ± 3.88

N. Vmax

Hill (nH)

74.18 ± 4.29

2.70 ± 1.19

Ka (µM)

n

7.23 ± 1.25

8

Figure 7. Activation of PKG Ia with the with peptide (SP). The kinase was preincubated with increasing concentrations of the
peptide as described in the variation protocol. 8 µM cGMP was used as a control. A: representative trace. B: trials had been combined and normalized to each trial’s respective cGMP control. The accompanying table gives the kinetic constants for SP with
normalized velocities.
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Simultaneous Activation with cGMP and Switch Peptide
Due to the close physical proximity of the nest and the cGMP binding site B, it had been
hypothesized that the presence of basal levels of cGMP would significantly affect the activation
kinetics of switch peptides. This was assessed by activating the kinase with the switch peptide in
the presence of low levels of cGMP (25 nM and 50 nM) (Figure 8). These concentrations are
well below those required for half-maximal PKG activation. In addition, previous reports estimated that the basal intracellular levels of cGMP are likely ranging from 20-50 nM.30,31 Though
the presence of cGMP slightly shifted the activation constant for the peptide, this change was
found to be insignificant in both cases. As predicted, the Vmin was increased with the addition of
cGMP, however the Vmax was slightly reduced in the 25 nM cGMP experiment. Furthermore, in
the 50 nM cGMP experimental set-up the cooperativity of peptide activation was markedly re-
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Figure 8. PKG activation with the switch peptide compared to activation with the switch peptide and basal levels of cGMP. Co-activation with
both 25 nM cGMP (A) and 50nM cGMP (B) was analyzed. In the accompanying tables, kinetic data is given comparing the coactivation trials
with their respective SP control. Velocity is given in µmol of W15 per minute*mg of PKG and Ka is given in µmol.
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C-Terminal Substitutions: Alanine Substitutions of Phenylalanine Residues
In order to probe the function of the phenylalanine residues within the knob, derivative
peptides were made. These derivatives were designed with an alanine-scanning approach. Alanine mutagenesis is a powerful technique to identify the functional role of amino acid side-chains
as each substitution removes side-chain atoms beyond the b-carbon.32 Alanine residues are used
because the methyl side chain is small in size and chemically inert. Because it retains a beta-carbon, it has the propensity to form alpha-helices. Glycine, which does not have a beta-carbon, is
more flexible and can cause conformational changes.32 In this study, alanine-scanning mutagenesis was used to determine the relationship between primary amino acid sequence and peptide activity. Amino acid side chains provide crucial noncovalent interactions between the peptide and
their respective binding site on the kinase.
In Moon et al (2015), it was posited that the dual phenylalanine residues constituting the
“knob” of the peptide, provide hydrophobic interactions on the B-site of the opposing protomer.
Each phenylalanine residue was mutated to alanine sequentially to assess the validity of this
claim in the context of the switch peptide. In a third peptide, both were substituted to alanine.
SP-F16A had the sequence YEDAEAKAKYEAEAAAFANLKLSD such that compared
to SP, the first phenylalanine residue has been substituted for an alanine residue. This peptide
showed similar efficacy and potency to the parent peptide with an activation constant of 5.53 µM
and a normalized velocity of 77%. The increase in cooperativity with a Hill coefficient of 3.44
was not significantly different from that of SP (Figure 9).
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Figure 9. Kinase activation with SP-F16A showed results similar to parent peptide, SP. A: representative trace for one trial is given, B:
all trials (n=6) are represented. This curve reached 77% of the cGMP control and had an activation constant of 5.5 µM. On the right, SPF16A is compared to SP which had activation at 74% of cGMP and a Ka of 7.2 µM. The accompanying table provides kinetic constants
for SP and SP-F16A with normalized velocities as a percent of the cGMP control.
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Similar results were observed when the second phenylalanine residue was substituted for
alanine. This peptide was termed SP-F17A and had the sequence YEDAEAKAKYEAEAAFAANLKLSD. The activation constant for this peptide was 5.36 µM and the normalized
velocity reached 81% of cGMP (Figure 10). With a Hill coefficient of 3.53, all three major ki-
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Figure 10. Activation of PKG Ia with SP-F17A. A: a representative trace for one trial is given, B: all trials are represented (n=8). The
accompanying table gives the kinetic constants for this peptide with normalized velocity as a percent of the cGMP control.
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Results from SP-F16A and -17A show that with only one phenylalanine residue in either
position, the peptides will still activate PKG. This led to the development of a third analog with
both phenylalanine residues substituted for alanine, creating a chain of 5 sequential alanine residues. This peptide was referred to as SP-F16,17A and it had the amino acid sequence
YEDAEAKAKYEAEAAAAANLKLSD. The activation constant of this peptide was 5.65 µM
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and the normalized velocity reached 73% (Figure 11).
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Figure 11. Activation of PKG Ia with SP-F16,17A. A: a representative trace is given, B: trace represents n=2. It is overlaid with
the trace for SP to show that this peptide’s activation kinetics are not significantly shifted from SP. The accompanying table gives
the kinetic constants with normalized velocity given as a percent of the cGMP control.
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Deletion Peptide
Next, a peptide was synthesized which had one phenylalanine residue removed. This
peptide is referred to as DSP and has the sequence: YEDAEAKAKYEAEAAF_ANLKLSD. This
peptide exhibited significantly reduced potency and efficacy. In fact, an activation constant and
maximal velocity could not be determined (higher concentrations could not be achieved due to
solubility issues of the peptides (Figure 12). Though this result was expected, it was hypothesized that further modifications to this shortened peptide may restore its functionality. Recalling
that N-terminal residues constitute the difference between S1.6, which failed to activate the kinase, and SP-F16,17A which activated just as well as SP, N-terminal residues of DSP were modified in assessing rescued the phenotypes. In addition, the C-terminus of the switch peptide has
been heavily investigated in previous studies, where C-terminal truncations resulted in inactive
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peptides.
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Figure 12. Activation of PKG Ia with DSP. Kinetic constants for this peptide are reported in the accompanying table. Velocities have
been normalized to the cGMP control. All trials are represented.

N-terminal Substitutions: Negatively Charged Residues
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N-Terminal Substitutions: Negatively Charged Residues
To determine if any N-terminal modifications could rescue the activity of the frameshifted peptide, a series of alanine scanning peptides were made. Charged residues were chosen
to be sequentially substituted because charged amino acids are critical to binding specificity.
The first of these peptides examined was named DSP-D3A and had the sequence
YEAAEAKAKYEAEAAFANLKLSD, such that compared to DSP, the third amino acid was
changed from a glutamic acid residue to alanine. DSP-D3A showed minimal efficacy and potency. The activation constant was 90.54 µM, demonstrating over a ten-fold shift in activity compared to SP (Figure 13). Additionally, the normalized velocity was only 29.77% of cGMP while
SP consistently shows ~70% activation. This suggests that the aspartic acid residue at position #
is not the sole caused of the poor activation seen in DSP.
DSP-E5A followed the alanine scanning rationale described above and consequently had
the next non-alanine residue substituted for alanine, giving it the sequence YEDAAAKAKYEAEAAFANLKLSD. This peptide gave similar results to DSP-D3A, with an activation constant
of 44.20 µM and a normalized velocity of 27.02% (Figure 13). This supports the results of DSPD3A illustrating that removal of negatively charged amino acids will not rescue the deleterious
phenotype caused by the deletion.
Results from the next alanine scanning analog, DSP-E11A, followed this pattern as well.
This peptide had the glutamic acid residue at position 11 in the parent peptide substituted for alanine (YEDAEAKAKYAAEAAFANLKLSD) and demonstrated similar potency and efficacy to
DSP-D3A and DSP-E5A. Specifically, the activation constant for DSP-E11A was 39.71 µM and
the normalized velocity was 27.62% of the cGMP control (Figure 13).
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The next alanine substitution was to the glutamic acid residue at position 13 in the parent
peptide giving it the sequence YEDAEAKAKYEAAAAFANLKLSD which was termed DSPE13A. This peptide continued the previously described pattern of significantly diminished potency and efficacy compared to SP. This peptide had an activation constant of 20.90 µM and a
maximum normal velocity of 29.83% (Figure 13).
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Figure 13. Activation of PKG Ia with analog peptides. Traces have been overlaid to compare their kinetics to each other and to the parent
peptide, SP. The accompanying table provides kinetic constants for these analogs as well as the parent peptides, SP and DSP. Velocities have
been normalized as a percent of cGMP controls.
* Hill values for DSP-E11A and DSP-E13A were fixed at 2.0. Prism8’s automatic curve fit function caused an artificially high Hill and ambiguous kinetic constants caused by a steep increase between two points.
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N-terminal Substitutions: Positively Charged Residues
After examining negatively charged residues, positively charged residues were scanned.
DSP-K7A, had the sequence YEDAEAAAKYEAEAAFANLKLSD, which contrasts previously
discussed DSP derivatives as the single residue substituted in this peptide was positively charged
lysine, instead of a negatively charged glutamic acid or aspartic acid. This peptide gave a moderately stored Ka compared at 15.46 µM, and efficacy was regained with a normalized velocity of
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72% (Figure 14).
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Figure 14. Activation of PKG Ia with DSP-K7A. A: representative trace for a single trial with its respective cGMP control. B: all
trials are represented and overlaid with the SP to compare activation of the derivative peptide to SP. The accompanying table gives
the kinetic constants for DSP-K7A and SP with normalized velocities.

28

The final DSP derivative was made such that lysine residue at position 9 in the parent
peptide was substituted for alanine. This peptide, with the sequence YEDAEAKAAYEAEAAFANLKLSD, was termed DSP-K9A. Results from this peptide mimicked that of DSPK7A with significantly restored potency, represented by Ka, and efficacy, represented by maximum velocity. The activation constant for DSP-K9A was 12.70 µM, which is nearly two-fold
shifted compared to SP but significantly improved from DSP-D3A, DSP-E5A, and DSP-E11A.
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The normalized velocity reached 65.97%, which is relatively comparable to SP (Figure 15).
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Figure 15. Activation of PKG Ia with DSP-K9A. A: representative trace for a single trial with its respective cGMP control. B: all
trials are represented and overlaid with the SP curve compare the kinetics of the derivative peptide with SP. The accompanying
table gives the kinetic constants for DSP-K9A and SP with normalized velocities.
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To expand on results from DSP-K7A and -K9A, the lysine to alanine substitution was
examined in context of the full-length peptide. SP-K9A and had the sequence
YEDAEAKAAYEAEAAFFANLKLSD such that both phenylalanine residues of the parent
pharmacophore are present and the lysine residue at position 9 has been changed to an alanine.
The Ka for this peptide was 11.70 µM and it reached a maximal normalized velocity of ~70%
(Figure 16). The observation that SP-K7A and -K9A yielded similar results to SP-K9A raises
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questions about the role of the lysine residues in the peptide-kinase interaction.
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Figure 16. Activation of PKG Ia with SP-K9A to assess the effect of the lysine substitution at position 9 in the context of the full-length
peptide. A: representative trace for one trial with its respective cGMP control. B: all trials are represented, and the trace is overlaid with
that of SP to compare the kinetics of the derivative peptide and SP. The accompanying table provides kinetic constants for SP-K9A and
SP with normalized velocities.
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Table 2 provides a summary of all peptides examined in this study. Listed is each peptide’s name, sequence, normalized minimum and maximum velocity, Hill coefficient, activation
constant (Ka) and number of trials.
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Table 2. Results from all peptide assays with Vmin, Vmax, Hill coefficient, activation constant and number of trials. Velocities
have been normalized to each trial’s respective cGMP control values.
* Hill values for DSP-E11A and DSP-E13A were fixed at 2.0. Prism8’s automatic curve fit function caused an artificially high
Hill and ambiguous kinetic constants caused by a steep increase between two points.
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DISCUSSION AND FUTURE DIRECTIONS

Pharmacophore Revisions
This study probed the function of residues within the “knob” of the switch peptide, previously created by Dostmann et al.3 Two successive phenylalanine residues were thought to provide a hydrophobic interaction with the “nest” located in the cGMP B-binding site of PKG Ia
and therefore allow these novel S-tides to bind to the kinase and cause activation.
Results from the SP-F16,17A peptide as well as SP-F16A and SP-F17A indicate that the
phenylalanine residues themselves are not necessary for peptide activity, which directly contrasts
results from the S1.1 peptide examined by Moon et al (2015). The difference between S1.1 and
SP-F16,17A is the length of the peptide, with S1.1 having additional peptides at the N-terminus.
These additional N-terminal residues were previously thought to only provide structure however
with SP-F16,17A as a direct parallel we can conclude that those additional residues on S1.1 prevented optimal activation of the kinase.
When one phenylalanine was deleted (DSP) from the knob, the DSP peptide showed
nearly no activation of the kinase. We hypothesize that this shift disrupts essential binding interactions either N-terminally or C-terminally from the deletion location. Removing charged residues that may be responsible for this effect could potentially save the phenotype. Both negative
and positively charged N-terminal residues were probed. Results from DSP analogs clearly
demonstrate that positively charged residues play a different role in binding than negatively
charged residues. Though substitution of negatively charged residues did not improve activity,
substitution of either lysine residue (DSP-K7A, -K9A) did improve both efficacy and potency to
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approximately the same level as SP. This suggests that positively charged residues may be responsible for the diminished activation by the DSP peptide. This hypothesis was further explored
with 3D modeling in the PyMol program. After modeling the interaction between the switch peptide and the nest, the location of both lysine residues was examined in an attempt to identify
charged or steric interactions that may have caused the phenotype exhibited by DSP-K7A, -K9A
(Figure 17). However, no obvious interactions were noted in the model and thus further studies
are required to determine the cause of the rescue effect and the exact role of the lysine residues.
To expand upon this work it is suggested that both lysine residues be substituted within the same
peptide. If our hypothesis is correct, this derivative should show activation similar to SP.

Figure 17. PyMol models of the switch peptide and PKG Ia B-site. Left: side view, right: top-view. Phe residues are represented in orange and
reside within the nest. Lys residues are indicated in magenta are and are distant from both charged areas on the B-site or significant structures
which would pose steric interaction.
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It is also possible that the alanine substitutions made in these peptides, which created a
string of multiple alanine residues, impaired the binding specificity of derivative peptides. In this
way, the peptide is able to bind to PKG in both the N- to C-terminus direction and the C- to Nterminus direction. This may suggest that the activating interaction between the peptide and PKG
is not caused by specific residues at a precise location in the sequence but rather any string of capable residues within the sequence. This theory could be further evaluated with retro-inverted
peptides. These peptides would maintain the same sequence as the parent peptide in question, but
with the N- and C-termini reversed.

Co-Activation of SP with cGMP
The nest site on PKG Ia and the cGMP-binding site are in close physical proximity. The
crystal structure of this protein illustrates a single ridge separating the two pockets (Figure 18).
It was hypothesized that because of the proximity of these two binding sites, the presence of
cGMP may affect the binding kinetics of the switch peptide. This was explored by performing
the kinase assay with the switch peptide as the activator with the addition of 25 nM or 50 nM
cGMP (Figure 8). In both experiments, with the addition of cGMP a predicted increase in Vmin
was observed and Vmax remained unchanged. Additionally, neither concentration of cGMP
caused a significant shift in the activation constant for the peptide. However, in the 50 nM experiment, there was a significant decrease in the Hill coefficient (nH). The Hill coefficient for the SP
control was 3.8, and after the addition of cGMP, nH was markedly reduced to 1.2. This suggests
that cGMP, at elevated concentrations, prevents cooperative activation by the peptides. The phenomenon of cooperativity inherently relies on multiple ligand binding sites, however peptide
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studies up to this point suggest the nest is the only location of peptide binding on PKG Ia. Therefore, the role of cGMP on the cooperativity of SP remains unclear.

Figure 18. Binding site proximity of the switch peptide and cGMP. The top image shows the crystal structure of the unbound Bsite. The bottom image has SP modeled (blue) such that it is interacting via the proposed mechanism with Phe residues providing a
hydrophobic interaction with the nest. The two sites are separated by a pronounced ridge, which is located at the center and runs
vertically in both images.
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Hill Coefficient
The Hill coefficient is used to describe cooperativity in ligand binding. A Hill coefficient
above 1 indicates that the binding of one ligand to an enzyme facilitates the binding of a second.
All peptides examined in this study had a Hill coefficient above 1, which suggests that the peptides exhibited positive cooperativity. This may be observed because the dimeric structure of the
kinase provides two nests which do not interact with the peptide independently. This hypothesis
could be explored by using a monomeric mutant PKG Ia in the peptide assays.18 If the dimerization of the kinase is responsible for the observed cooperativity, using a monomeric version of the
kinase should reduce the Hill coefficient below 1.

Concentration-Dependent Effects on PKG Ia activity
At the highest peptide concentrations tested, it was noted that the activity of the kinase
began to decrease instead of the predicted plateau (see Figures 9,14, 15, 16). This highly repeatable effect was observed for multiple peptides in this study as well previous studies. This may
suggest that at high concentrations, the peptide activators begin to interact with the substrate itself. This hypothesis could be tested by using a different peptide substrate and seeing if the drop
in activity occurs. Future studies could also examine this effect by incrementally increasing peptide concentrations beyond concentrations used in this study to determine how far activity could
be reduced in this way.
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Conclusion
An estimated 73M Americans have hypertension; however most respond poorly to current treatments. Uncontrolled hypertension leads to increased risk of stroke, heart attack, congestive heart failure, and kidney failure. There remains a significant unmet need for novel antihypertensive agents with improved efficacy and fewer side effects. None of the existing hypertension
drugs target PKG, an enzyme critically responsible for mediating arterial dilation.
A peptide library directly targeting cGMP-dependent protein kinase (PKG) has been developed, however the pharmacophore of the lead peptide (SP) had not yet been solidified. It was
hypothesized that two phenylalanine residues toward the C-terminus of the peptide provide crucial hydrophobic interactions which allow the peptide to activate the kinase. In this study it was
observed that in the context of SP, neither phenylalanine residue is necessary for peptide-mediated activation of PKG. Though deleting one phenylalanine residue caused a marked reduction in
potency and efficacy, substituting either lysine residue N-terminal from the deletion to alanine
rescued the peptide’s ability to activate the kinase.
Our peptides show dose-dependent activation specifically for the vascular PKG isoform,
resulting in a rapid and reversible onset of action. These peptides have been demonstrated to promote 20-50% blood pressure reductions in rodent models of hypertension. This approach may
provide immediate clinical benefit as an IV-administered drug for acute hypertensive crisis or may
serve as a platform for oral/subcutaneous therapeutics for resistant hypertension.
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